Assessment of Safety and Satisfaction Toward COVID-19 Vaccines.

Assessment of Safety and Satisfaction Toward COVID-19 Vaccines: A Cross-sectional Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05857176

Enrollment

508

Registered

2023-05-12

Start date

2021-12-15

Completion date

2022-02-10

Last updated

2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Vaccine Adverse Reaction

Brief summary

This is a cross-sectional, web-based online survey done with the use of a Google Form-questionnaire to gather information from the general public regarding their knowledge, satisfaction, and tolerability about the COVID-19 vaccine.

Detailed description

* A cross-sectional study was conducted. The subjects participating in the study are residents in Egypt. * An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin). * The questionnaire comprised two categories of inquiries. The first is demographic data of the subject. The second is questions about COVID-19 vaccine-related data, such as whether had taken the vaccine or not, the type of vaccine administered, side effects encountered from the vaccine , if got enough information regarding the vaccine and where obtain the vaccine information from and if reluctant to taking the vaccine and the reasons for hesitancy. All participants were permitted to terminate the survey at any time of the study.

Interventions

OTHERCOVID-19 Vaccine questionnaire

An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* all adults (age ≥ 18 years) complete the questionnaire were considered eligible to participate in the survey.

Exclusion criteria

* Incomplete questionnaires were excluded from the final analysis.

Design outcomes

Primary

Measure	Time frame	Description
headache incidence	3 month	Pecentage
fever incidence	3 month	Pecentage
fatigue incidence	3 month	Pecentage
pain at site of injection incidence	3 month	Pecentage

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026